Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting

Rhea-AI Summary

Kintara Therapeutics (Nasdaq: KTRA) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, Florida. The company will present data on its investigational drug VAL-083, focused on treating RELA fusion-positive ependymoma and recurrent glioblastoma. Two abstracts will be shared: one detailing case studies of VAL-083 in patients with ependymoma and glioma under an expanded access program, and another highlighting findings from 24 recurrent glioblastoma patients. Kintara is dedicated to developing innovative cancer therapies, with VAL-083 currently being advanced in the GBM AGILE registrational study.

Positive

• Kintara will present data on VAL-083 at the 2023 AACR Annual Meeting, highlighting its potential effectiveness in treating rare tumors.
• The ongoing GBM AGILE Study indicates a structured clinical trial approach for VAL-083, enhancing its credibility.
• Clinical data from the expanded access programs show promising results in difficult-to-treat patient populations.

Negative

• Kintara has paused the REM-001 program for cutaneous metastatic breast cancer to conserve cash resources.

SAN DIEGO, April 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Florida  from April 14 through April 19, 2023, where VAL-083 data will be presented.

Data Presentations:

Session Title: Late-Breaking Research: Clinical Research 1 / Endocrinology 
Poster Section 34, Presentation Time: Monday, April 17, 2023 - 1:30 to 5:00 p.m. ET

Abstract LB126: RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports

The abstract describes two patient case reports, one with ependymoma and one with diffuse midline glioma, treated with VAL-083 under an expanded access program. The cases highlight that VAL-083 may be a treatment option for recurrent RELA fusion-positive ependymoma and diffuse midline glioma refractory to other treatments. Safety and efficacy data will be updated at the poster presentation at the meeting.

Abstract LB127: VAL-083 in patients with recurrent glioblastoma treated under expanded access program

The abstract reports on background characteristics, and safety and efficacy measures, from 24 patients with recurrent GBM treated with VAL-083 under an expanded access program. Use of VAL-083 continues to show benefit in the treatment of GBM patients who have had multiple recurrences and have limited therapeutic options. This information will be updated in the poster presentation at the meeting.

ABOUT KINTARA

Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a 'first-in-class', small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.

Kintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. Kintara has paused the REM-001 CMBC program to conserve cash resources.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.

SAFE HARBOR STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE Study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; global unrest; and the continued impact of the COVID-19 pandemic.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2022, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS

Investors
LifeSci Advisors 
Mike Moyer, Managing Director 
617.308.4306 
mmoyer@lifesciadvisors.com

Media Inquiries
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858.717.2310
646.942.5604
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-data-presentation-at-the-2023-american-association-for-cancer-research-annual-meeting-301797343.html

SOURCE Kintara Therapeutics

FAQ

What is Kintara Therapeutics presenting at the AACR Annual Meeting 2023?

Kintara is presenting data on VAL-083, focusing on its treatment potential for RELA fusion-positive ependymoma and recurrent glioblastoma.

When is Kintara Therapeutics presenting data on VAL-083?

The data will be presented on April 17, 2023, during the Late-Breaking Research session of the AACR Annual Meeting.

What are the key findings from Kintara's VAL-083 case reports?

The case reports suggest that VAL-083 may be effective for patients with RELA fusion-positive ependymoma and recurrent glioblastoma who have exhausted other treatment options.

What recent challenges has Kintara Therapeutics faced?

Kintara has paused the REM-001 program aimed at treating cutaneous metastatic breast cancer due to cash conservation efforts.